Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Memory | 2 | 2021 | 184 | 1.330 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 393 | 1.220 |
Why?
|
| Dendritic Cells | 6 | 2020 | 403 | 1.150 |
Why?
|
| Immunotherapy | 3 | 2019 | 660 | 0.810 |
Why?
|
| Dog Diseases | 2 | 2020 | 49 | 0.790 |
Why?
|
| Receptors, IgG | 1 | 2021 | 54 | 0.720 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2021 | 501 | 0.700 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 38 | 0.620 |
Why?
|
| Doxorubicin | 1 | 2019 | 300 | 0.570 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 45 | 0.560 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 186 | 0.560 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 157 | 0.520 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 993 | 0.450 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2013 | 59 | 0.410 |
Why?
|
| Vaccines | 1 | 2017 | 370 | 0.400 |
Why?
|
| Influenza A virus | 1 | 2013 | 138 | 0.390 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 1697 | 0.330 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 51 | 0.310 |
Why?
|
| Amino Acyl-tRNA Synthetases | 2 | 2024 | 26 | 0.270 |
Why?
|
| Animals | 13 | 2024 | 33798 | 0.250 |
Why?
|
| Mice, Inbred BALB C | 3 | 2020 | 1003 | 0.250 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 4288 | 0.220 |
Why?
|
| Dogs | 2 | 2020 | 765 | 0.190 |
Why?
|
| Cannabidiol | 1 | 2020 | 21 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 533 | 0.180 |
Why?
|
| Immune System | 1 | 2020 | 87 | 0.170 |
Why?
|
| Arthralgia | 1 | 2020 | 54 | 0.170 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 79 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 195 | 0.170 |
Why?
|
| Homeostasis | 1 | 2024 | 683 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 324 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2011 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 96 | 0.170 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 201 | 0.160 |
Why?
|
| Osteoarthritis | 1 | 2020 | 86 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 320 | 0.150 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 92 | 0.150 |
Why?
|
| Immunophenotyping | 1 | 2019 | 328 | 0.150 |
Why?
|
| Mice | 6 | 2024 | 17542 | 0.140 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 65 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 100 | 0.140 |
Why?
|
| Peptides | 1 | 2020 | 792 | 0.130 |
Why?
|
| Bystander Effect | 1 | 2016 | 7 | 0.130 |
Why?
|
| B7 Antigens | 1 | 2016 | 11 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 290 | 0.130 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 312 | 0.130 |
Why?
|
| Cytokines | 2 | 2025 | 1284 | 0.120 |
Why?
|
| Cytosol | 1 | 2015 | 158 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1237 | 0.120 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 52 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2017 | 499 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 89 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2017 | 608 | 0.120 |
Why?
|
| Immunomodulation | 2 | 2024 | 81 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1473 | 0.110 |
Why?
|
| Vaccination | 1 | 2019 | 944 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2017 | 940 | 0.110 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2013 | 11 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2019 | 3040 | 0.100 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 60 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2015 | 372 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 576 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 668 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1386 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 4357 | 0.070 |
Why?
|
| Th1 Cells | 2 | 2020 | 152 | 0.070 |
Why?
|
| Open Reading Frames | 1 | 2006 | 210 | 0.060 |
Why?
|
| Humans | 8 | 2025 | 123180 | 0.060 |
Why?
|
| Genome, Insect | 1 | 2006 | 95 | 0.060 |
Why?
|
| Multigene Family | 1 | 2006 | 298 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2006 | 327 | 0.060 |
Why?
|
| Female | 3 | 2024 | 65562 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2025 | 399 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2017 | 12142 | 0.050 |
Why?
|
| Drosophila | 1 | 2006 | 766 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2006 | 707 | 0.040 |
Why?
|
| Cannabis | 1 | 2020 | 41 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2024 | 520 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 250 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 2840 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3291 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1585 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2016 | 48 | 0.030 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 12 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 2695 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 54 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 350 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 664 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 345 | 0.030 |
Why?
|
| Neoplasms | 2 | 2020 | 2756 | 0.030 |
Why?
|
| Male | 1 | 2019 | 60173 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 467 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 831 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2524 | 0.020 |
Why?
|
| Macrophages | 1 | 2015 | 605 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1268 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 4494 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1403 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2307 | 0.020 |
Why?
|
| Species Specificity | 1 | 2006 | 548 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1702 | 0.010 |
Why?
|